Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (5959)	3/17/1998 5:36:00 PM
From: Neil_L	Respond to of 23519

It seems one should trade MCHM and ZONA on VVUS's news...both had a strong day on no news that I could find. Neil.

To: RT who wrote (5959)	3/17/1998 5:43:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 23519

RT, Once the official approval letter is received, it should only take a couple weeks for Viagra to hit pharmacy shelves and for samples to be in physician's offices. It should become available mid-April with the official product launch set for early May. Bradpalm1

To: RT who wrote (5959)	3/17/1998 5:56:00 PM
From: Neil_L	Respond to of 23519

Found this on the wire: Pfizer Sees 2Q Launch Of Impotency Drug Pending FDA OK NEW YORK (Dow Jones)--Pfizer Inc. (PFE) plans to put its new impotency pill on the market during the second quarter pending Food and Drug Administration approval, spokesman Brian McGlynn said. The FDA had put the drug, known as Viagra, on fast-track review, committing itself to act on the application within six months, or by the end of March. The timing of Viagra's release is crucial, because the drug is vying for market share with a number of other male impotency cures. As a pill, Viagra enjoys a marketing advantage that a timely launch would enhance. Other companies with impotency products are Zonagen Inc. (ZONA), whose Vasomax will be marketed by Schering-Plough Corp. (SGP) pending FDA approval, and Vivus Inc. (VVUS), whose Muse product is already on the market. Between 10 million to 20 million men in the U.S. will suffer impotency at some point in their lives. Analysts say first-year sales for Viagra could be about $300 million to $400 million. -Sean Davis; 201-938-5244 "Dow Jones News Service" "Copyright(c) 1998, Dow Jones & Company, Inc."